本文已被:浏览 0次 下载 0次
投稿时间:2024-08-29
投稿时间:2024-08-29
中文摘要: 为评价扛板归多糖体外抗肿瘤活性,通过细胞计数试剂盒(cell counting kit-8,CCK-8)方法测定扛板归多糖对HepG2 细胞的体外增殖抑制作用。运用5-乙炔基-2′-脱氧尿嘧啶核苷(5-ethynyl-2′-deoxyuridine,EdU)增殖试验、细胞Hoechst 染色试验、线粒体膜电位检测试验、蛋白质免疫印迹试验探究扛板归多糖对肝癌HepG2 细胞的抑制作用机制。结果表明:扛板归多糖可以显著抑制HepG2 细胞增殖,并呈一定的剂量依赖性,半数抑制浓度为130.81 μg/mL。在扛板归多糖作用下,HepG2 细胞细胞核固缩、细胞核碎片增加,表现出凋亡特征。扛板归多糖使HepG2 细胞线粒体膜电位显著下降;电压依赖性阴离子通道1(voltage-dependent anion channel l,VDAC1)、Bax、Caspase-3 蛋白表达显著上调,而Bcl-2、Mitofusin2 蛋白表达下调,均呈现量效相关性。综上,扛板归多糖能够抑制HepG2 细胞增殖,可能与影响线粒体功能促进细胞凋亡有关。
Abstract:The antitumor activity in vitro of polysaccharides from Polygonum perfoliatum L. was evaluated.The inhibitory effect of the polysaccharides on the proliferation of HepG2 cells in vitro was evaluated by the cell counting kit-8(CCK-8)assay.The 5-ethynyl-2′-deoxyuridine(EdU)assay,Hoechst staining,mitochondrial membrane potential assay,and Western blotting were employed to explore the inhibitory mechanism.The results showed that the polysaccharides from P.perfoliatum inhibited the proliferation of HepG2 cells in a concentration-dependent manner,with the half maximal inhibitory concentration(IC50)of 130.81 μg/mL. After treatment with the polysaccharides,HepG2 cells showed nuclear pycnosis,increased nuclear fragmentation,and apoptosis.The polysaccharides decreased the mitochondrial membrane potential,up-regulated the expression of voltage-dependent anion channel l(VDAC1),Bcl-2-associated X protein(Bax),and cysteinyl aspartate-specific proteinase-3(Caspase-3),and down-regulated the expression of B-cell lymphoma-2(Bcl-2)and Mitofusin2 in a concentration-dependent manner.In conclusion,the polysaccharides from P.perfoliatum inhibited HepG2 cells by affecting mitochondrial function and promoting cell apoptosis.
keywords: Polygonum perfoliatum L. polysaccharides HepG2 cell in vitro antiproliferative activity antitumor activity
文章编号:202505002 中图分类号: 文献标志码:
基金项目:国家自然科学基金地区科学基金项目(82160059);广西自然科学基金项目(2020GXNSFAA259025);广西大学生创新创业训练计划项目(202410594023、S202410594025)
作者 | 单位 |
韦啟球1,2,3,王思思1,2,3,梁柳春1,2,3,闭爱艳4,裴世成1,2,3,伍善广1,2,3,刘雪萍1,2,3* | 1.广西科技大学医学部,广西 柳州 545005;2.广西高校医工融合创新研究重点实验室,广西 柳州 545005;3.柳州市桂中特色药用资源开发重点实验室,广西 柳州 545005;4.广西医科大学药学院,广西 南宁 530021 |
引用文本: